Maxitram Sr

Tramadol Hydrochloride, the active ingredient in Maxitram Sr, is an opioid analgesic presented as an oral formulation for oral use. It is prescribed for the management of moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Maxitram Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxitram Sr (Tramadol) is used to relieve pain by acting on central pain pathways. - Postoperative pain: provides effective relief after surgical procedures. - Cancer‑related pain: helps control moderate to severe pain associated with malignancies. - Chronic musculoskeletal pain: reduces persistent pain from conditions such as osteoarthritis or back pain.

Tramadol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Dizziness - Constipation - Headache - Drowsiness - Dry mouth

Serious or Rare Side Effects: - Seizures - Respiratory depression - Serotonin syndrome - Severe allergic reactions (e.g., anaphylaxis) - Cardiac arrhythmias - Marked hypotension

When prescribing Tramadol, clinicians should consider several safety measures. - Renal or hepatic impairment: adjust dose or monitor closely. - Elderly patients: start with the lowest effective dose. - Discontinuation: avoid abrupt cessation to reduce withdrawal risk. - Dependence potential: assess for signs of misuse. - Contraindicated in patients with severe respiratory depression. - Store at ambient temperature: keep in the original container, protect from moisture.

Tramadol can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonin toxicity. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential for altered bleeding risk. - Antihypertensive agents: possible enhancement of hypotensive effects.